Welcome to our dedicated page for Check Cap news (Ticker: CHEK), a resource for investors and traders seeking the latest updates and insights on Check Cap stock.
News and filings around Check-Cap Ltd. (NASDAQ: CHEK) trace the company’s evolution from a clinical stage medical diagnostics developer into a business centered on embodied artificial intelligence through its merger with MBody AI. Historically, Check-Cap announcements focused on its C-Scan® investigational device, an ingestible imaging capsule designed for preparation-free colorectal cancer screening, along with regulatory milestones and shareholder communications about its intellectual property and strategic alternatives.
More recent news is dominated by the definitive Agreement and Plan of Merger with MBody AI, a Nevada corporation described as a market leader in embodied artificial intelligence. Press releases and Form 6-K reports highlight shareholder approval of the merger, plans to rename the combined company “MBody AI Ltd.”, and the strategic rationale of combining Check-Cap’s legacy assets with MBody AI’s AI orchestration platform. Coverage includes details of the MBody AI Orchestrator™ platform, its hardware-agnostic architecture, and its deployment across Fortune 500 enterprises and blue-chip brands.
Investors following CHEK news can expect updates on merger progress, shareholder meeting outcomes, Nasdaq listing and compliance matters, and any financing or capital markets activity tied to the combined company’s growth strategy. Additional items include legal and governance-related press releases, as well as communications about Check-Cap’s acquisition of exclusive Ghost Kitchen franchise rights in New Jersey. This news feed offers a consolidated view of corporate developments, strategic transactions, and regulatory disclosures that shape the investment narrative for CHEK.
For those tracking the transition from medical diagnostics to embodied AI and related automation themes, the CHEK news page provides ongoing context on how Check-Cap and MBody AI present their business model, market positioning and long-term plans through official announcements and SEC-furnished materials.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Check-Cap Ltd. (NASDAQ: CHEK, CHEKZ) announced financial results for Q4 and the full year ended December 31, 2022. The company reported a net loss of $3.7 million for Q4 2022, down from $5.5 million in Q4 2021. R&D expenses for the year rose to $14.3 million from $12.3 million, while general and administrative expenses increased to $5.8 million compared to $5.0 million in 2021. The company’s cash position at year-end was $42.1 million, which is projected to fund operations into Q4 2024. However, the initiation of the powered portion of its pivotal U.S. study is postponed as current efficacy results do not meet the required goals.